J&J looks to buy Ollin Biosciences for up to $3.4 billion, FT says

By Reuters News

- Johnson & Johnson JNJ.N could announce a deal as soon as Monday to buy Texas-based biotech Ollin Biosciences for up to $3.4 billion, the Financial Times said, citing people familiar with the matter.

Here are some details:

  • Under the terms being discussed, J&J could pay Ollin's backers $2.2 billion in cash upfront and a further $1.2 billion in potential milestone payments, the paper said

  • Ollin raised $330 million in June to advance late-stage studies of its experimental eye disease drug OLN324, to treat diabetic macular edema (DME) and wet age-related macular degeneration (AMD), two leading causes of vision loss

  • Reuters could not immediately verify the report. Neither Johnson & Johnson nor Ollin Biosciences immediately responded to Reuters' requests for comment outside business hours

  • J&J acquired biotech Firefly Bio for $1 billion in cash this year, as it looked to expand its cancer drug pipeline. The company also bought drugmaker Intra-Cellular Therapies for $14.6 billion in 2025 to boost its presence in the market for neurological disorder treatments


Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.